13 completed, 2 unknown, 1 enrolling by invitation, 1 recruiting. 4 Phase 2, 4 Phase 3, 3 Not applicable, 2 Phase 1, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 3, Terminated 1 |
| Phase 3 | 4 | Completed 3, Withdrawn 1 |
| Not applicable | 3 | Completed 3 |
| Phase 1 | 2 | Completed 2 |
| Early Phase 1 | 1 | Completed 1 |
| Phase 4 | 1 | Enrolling by invitation 1 |
Follow ioflupane: new trials by email Literature Review of ioflupane trials Research Report on ioflupane
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety, Biodistribution, Internal Radiation Dosimetry, and Effective Dose of DaTSCAN™ Ioflupane (123I) Injection in Chinese Healthy Volunteers. DaTSCAN™ Ioflupane (123I) Injection - Healthy Subjects (HS) | Phase 1 | Completed | GE Healthcare | 9 | 2021-05-13 | 2023-08-02 |
| Markers of Disease Progression and Gait Within the Parkinsonian Population The FeetMe® Evaluation, the PKG® Watch,, MRI - Parkinson Disease | Not applicable | Completed | University Hospital, Lille | 83 | 2020-12-22 | 2025-12-04 |
| A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients DaTSCAN™ Ioflupane (123I) Injection - Parkinsonian Syndrome, Parkinson Disease(PD) | Phase 3 | Completed | GE Healthcare | 172 | 2020-06-28 | 2023-10-16 |
| Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease DaTscan, F18-AV-45, FDG-PET - Alzheimer's Disease, Lewy Body Dementia | Recruiting | Douglas Scharre | 76 | 2018-08-30 | 2026-10-15 | |
| Quantitative Mapping of Substantia Nigra Iron in Parkinson's Disease (Stages I-IV, REM Sleep Behavior Disorder) and Controls (11C)PE2I, Ioflupane - Parkinson Disease, REM Sleep Behavior Disorder | Phase 1 / Phase 2 | Completed | Weill Medical College of Cornell University | 82 | 2018-08-14 | 2025-03-12 |
| Idiopathic Parkinson's Progression and Dopamine Transporter SPECT Ioflupane I 123 - Parkinson Disease | Completed | Julie Gurwell | 12 | 2018-01-19 | 2022-11-17 | |
| Diagnostic Imaging for Clear Cell Renal Cell Carcinoma Ioflupane I123 - Clear Cell Renal Cell Carcinoma | Phase 2 | Terminated | Region Skane | 5 | 2017-07-14 | 2019-06-21 |
| A Cross-Over, Multi-Center Trial to Evaluate the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes NAV5001, DaTscan - Parkinson's Syndrome | Phase 3 | Withdrawn | Navidea Biopharmaceuticals | 2017-04-01 | 2017-09-13 | |
| Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain [18F]MNI-958, [18F]Florbetapir, DaTscan - Alzheimer Disease, Healthy Volunteers | Early Phase 1 | Completed | Molecular NeuroImaging | 12 | 2016-11-29 | 2019-03-25 |
| Nigrosomal Iron Imaging in Parkinson's Disease Patient assessment, DATScan, Orbital X-Ray - Parkinson Disease | Unknown | University of Nottingham | 145 | 2016-06-01 | 2018-10-12 | |
| Systemic Synuclein Sampling Study (S4) Biofluid samplings, Tissue samplings, DaTSCAN™ - Parkinson's Disease | Completed | Michael J. Fox Foundation for Parkinson's Research | 80 | 2015-10-01 | 2017-08-17 | |
| Validation of DaTscan for Detection of Parkinson Disease Related Disorders l-123 Ioflupane - Parkinson Disease, Movement Disorders | Unknown | Wisconsin Institute for Neurologic and Sleep Disorders S.C. | 20 | 2014-07-01 | 2014-07-16 | |
| Study of Dopamine and Serotonin Transporters in Patients With Amyotrophic Lateral Sclerosis and Controls SPECT : 123 I-FP-CIT (DATSCAN) and 123I-ADAM - Amyotrophic Lateral Sclerosis | Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 16 | 2012-10-01 | 2015-05-13 |
| DaTSCAN Imaging in Aging and Neurodegenerative Disease I-123 Ioflupane solution injection prior to SPECT scan (DaTscan), Single photon emission computed tomography (SPECT) scan - Dementia, Parkinsonism | Phase 4 | Enrolling by invitation | Mayo Clinic | 500 | 2011-10-01 | 2026-03-10 |
| Study to Identify Clinical, Imaging and Biologic Markers of Parkinson Disease Progression DaTscan - Parkinson Disease | Phase 2 | Completed | Ken Marek, MD | 952 | 2010-06-01 | 2023-11-14 |
| Imaging of Vesicular Acetylcholine and Dopamine Transporters in Dementia With Lewy Bodies Imaging with IBVM, Imaging with DATSCAN, neuropsychological evaluation - Dementia With Lewy Bodies | Not applicable | Completed | University Hospital, Bordeaux | 34 | 2009-05-01 | 2026-05-14 |
| Dopaminergic Loss and Pain in Parkinson's Disease ioflupane 123I (DATSCAN®) - Parkinson's Disease, Pain | Phase 2 | Completed | University Hospital, Toulouse | 20 | 2009-03-01 | 2020-07-29 |
| Study of the Effects of Dopaminergic Medications on Dopamine Transporter Density in Subjects With Parkinson's Disease cabergoline, carbidopa/levodopa, DATscan and SPECT imaging - Parkinson Disease, Parkinsonian Syndrome | Not applicable | Completed | Institute for Neurodegenerative Disorders | 30 | 2005-01-01 | 2009-08-28 |
| Dopamine Transporter Scintigraphy Imaging (DAT-Imaging) in Patients With Lewy Body Dementia DatSCAN - Lewy Body Dementia, Non-DLB Dementia | Phase 3 | Completed | GE Healthcare | 326 | 2003-11-01 | 2007-05-16 |
Parkinson Disease (12) · Disease (3) · Lewy Body Disease (3) · Parkinsonian Disorders (3) · Alzheimer Disease (2) · REM Sleep Behavior Disorder (2) · Supranuclear Palsy, Progressive (2) · Amyotrophic Lateral Sclerosis (1) · Carcinoma, Renal Cell (1) · Cognitive Dysfunction (1) · Dementia (1) · Dementia, Vascular (1) · Essential Tremor (1) · Mobility Limitation (1) · Movement Disorders (1)
GE Healthcare (3) · Assistance Publique - Hôpitaux de Paris (1) · Douglas Scharre (1) · Institute for Neurodegenerative Disorders (1) · Julie Gurwell (1) · Ken Marek, MD (1) · Mayo Clinic (1) · Michael J. Fox Foundation for Parkinson's Research (1) · Molecular NeuroImaging (1) · Navidea Biopharmaceuticals (1) · Region Skane (1) · University Hospital, Bordeaux (1) · University Hospital, Lille (1) · University Hospital, Toulouse (1) · University of Nottingham (1)
United States (9) · France (5) · Germany (3) · Austria (2) · China (2) · Italy (2) · Spain (2) · United Kingdom (2) · Australia (1) · Canada (1) · Greece (1) · Israel (1) · Norway (1) · Sweden (1)
John P Seibyl, MD (2) · Kenneth L Marek, MD (2) · Alexander Shtilbans, MD (1) · Andrew Singleton, PhD (1) · Arthur W. Toga, PhD (1) · Biao LI (1) · Bradley Boeve, MD (1) · Caroline Moreau, MD,PhD (1) · Christine Brefel-Courbon, MD (1) · Christopher Coffey, PhD (1) · Cornelia Reininger, M.D. Ph.D. (1) · Douglas W Scharre, MD (1) · John Q. Trojanowski, MD, PhD (1) · Julie Gurwell, PhD, PA-C (1)
PMID 24993764, PMID 25710187, PMID 26534930, PMID 27469360, PMID 28958801, PMID 28986467, PMID 29247084, PMID 29560382, PMID 30706197, PMID 31678032, PMID 32073681, PMID 32198310, PMID 33348363, PMID 33408148, PMID 33422890, PMID 33790041, PMID 36844148, PMID 36849448, PMID 37029298, PMID 37332638, PMID 37451695, PMID 37491235, PMID 37586882, PMID 38169864, PMID 39043465, PMID 39627057, PMID 39644799, PMID 40164470, PMID 40626875, PMID 40705614, PMID 41094519, PMID 41453126, PMID 42393590
2016 (1), R01NS095562 (1)